Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Tolerogenic Programming Promotes Human Cytomegalovirus Permissiveness in Dendritic Cells.

Created on 28 Oct 2026

Authors

Katharina Rahmel-Stein, Jennifer Becker, Berenike Lange, Luise Krajewski, Britta Eiz-Vesper, Ulrich Kalinke

Published in

European journal of immunology. Volume 56. Issue 10.

Abstract

Dendritic cells (DCs) are important targets of human cytomegalovirus (HCMV), yet the factors determining their permissiveness to infection remain incompletely understood. We previously identified a CD1a-/CD86- monocyte-derived DC (moDC) subset with a tolerogenic transcriptional profile and increased susceptibility to HCMV. To test whether tolerogenic programming promotes DC permissiveness, we generated tolerogenic DCs (tolDCs) using vitamin D3 (VitD3), dexamethasone (Dexa), or their combination. TolDCs treated with Dexa alone or with VitD3+Dexa showed a maturation-resistant phenotype, whereas VitD3-treated cells retained partial responsiveness to maturation stimuli. Compared with conventional moDCs, tolDCs were more susceptible to HCMV infection. Functionally, HCMV-exposed tolDCs induced markedly weaker CD4+ and CD8+ T-cell proliferation, with Dexa-treated cells showing the lowest stimulatory capacity. Together, these findings identify tolDCs as a permissive niche for HCMV and suggest that the virus may exploit regulatory DC states to evade immune control.

PMID:
42947569
Bibliographic data and abstract were imported from PubMed on 28 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement